ASCO: Adding Curcuminoids to Docetaxel Shows Promise in Castration-Resistant Prostate Cancer

Addition of curcuminoids to treatment with docetaxel was well tolerated and showed promise in improving the response rate to docetaxel “in terms of both PSA decrease and objective response” in a phase II trial in patients with castration-resistant prostate cancer.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news